Bumetanide injection for treatment of edema in heart, liver, and kidney diseases

Bumetanide injection is a potent loop diuretic administered intravenously or intramuscularly to treat edema related to congestive heart failure, liver disease, and kidney disorders including nephrotic syndrome. It has a rapid onset of action and short duration, promoting increased urine output by blocking sodium and chloride reabsorption in the kidney's loop of Henle.

Bumetanide injection is used for the treatment of edema in adults and pediatric patients associated with:

• Congestive heart failure
• Hepatic disease including cirrhosis and ascites
• Renal disease, including nephrotic syndrome

It is administered parenterally when oral absorption is impaired or oral administration is not feasible.

Bumetanide

Bumetanide works by inhibiting sodium and chloride reabsorption primarily in the ascending limb of the loop of Henle in the kidney. This interference increases urine production (diuresis) by preventing water reabsorption. It also increases potassium excretion and affects phosphate reabsorption indicating additional action in the proximal tubule. Diuresis begins within minutes of intravenous administration and peaks within 15 to 30 minutes.

Bumetanide injection is supplied as a sterile solution at 0.25 mg/mL for intravenous or intramuscular use. The dose and frequency must be carefully adjusted to individual patient needs to avoid excessive diuresis and electrolyte imbalances.

For neonates and infants, doses and clearance rates vary with age, requiring careful monitoring.

• Anuria (absence of urine production)
• Severe electrolyte depletion until corrected
• Hepatic coma
• Known hypersensitivity to bumetanide

Discontinue if marked increase in blood urea nitrogen or creatinine or development of oliguria occurs during therapy in patients with progressive renal disease.

• Excessive dosing can cause profound diuresis leading to dehydration, electrolyte depletion, circulatory collapse, and risk of vascular thrombosis particularly in elderly patients.
• Hypokalemia is a significant risk; monitoring and potassium supplementation may be necessary, especially in patients with heart failure, hepatic cirrhosis with ascites, potassium-losing nephropathies, or ventricular arrhythmias.
• In hepatic cirrhosis with ascites, rapid electrolyte changes can precipitate hepatic encephalopathy and coma, necessitating in-hospital initiation with close monitoring.
• Ototoxicity risk exists, especially with high doses or impaired renal function, and potential additive risk with aminoglycoside antibiotics.
• Patients allergic to sulfonamides may show hypersensitivity.
• Rare thrombocytopenia has been reported; patients should be regularly monitored for blood abnormalities.

• Common: Electrolyte disturbances including hypokalemia, hypomagnesemia, hypocalcemia; dehydration; increased uric acid leading to hyperuricemia; transient elevations of blood urea nitrogen and creatinine especially with dehydration or renal impairment.
• Serious but rare: Ototoxicity; thrombocytopenia; allergic reactions in sulfonamide-sensitive patients.

• Aminoglycoside antibiotics: Increased ototoxicity risk; concurrent use with parenteral bumetanide should be avoided unless life-threatening.
• Lithium: Decreased renal clearance and increased toxicity risk; coadministration not recommended.
• Probenecid: Reduces bumetanide natriuretic effect by inhibiting renal tubular secretion; concurrent use contraindicated.
• Indomethacin: Reduces bumetanide-induced urine output and sodium excretion; concurrent use not recommended.
• Antihypertensives: Potentiation of effects may require dose adjustment.
• Digoxin and anticoagulants (warfarin): No interaction on blood levels reported.

Pregnancy

Bumetanide is not teratogenic in mice and hamsters at very high doses but showed slight embryocidal and developmental effects in rats and rabbits at doses much higher than human therapeutic levels. There are no adequate well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation

It is unknown if bumetanide is excreted in human milk. Nursing is generally not recommended during treatment.